July 6 (Reuters) - BELLUS Health Inc BLU.TO :
* BELLUS HEALTH ANNOUNCES TOPLINE RESULTS FROM ITS PHASE 2 RELIEF TRIAL OF BLU-5937 FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH
* BELLUS HEALTH INC - PRIMARY ENDPOINT OF PLACEBO-ADJUSTED REDUCTION IN AWAKE COUGH FREQUENCY DID NOT REACH STATISTICAL SIGNIFICANCE
* BELLUS HEALTH INC - BLU-5937 WAS WELL TOLERATED WITH LOW IMPACT ON TASTE PERCEPTION; SAFETY PROFILE COMPARABLE TO PLACEBO
* BELLUS HEALTH INC - PATIENT ENRICHMENT STRATEGY WITH HIGHER COUGH COUNT PATIENTS TO BE PURSUED IN ADAPTIVE PHASE 2B TRIAL EXPECTED TO START IN Q4 2020
* BELLUS HEALTH- CLINICALLY MEANINGFUL REDUCTIONS IN PLACEBO ADJUSTED AWAKE COUGH FREQUENCY ACHIEVED IN PRE-SPECIFIED ANALYSIS OF HIGH COUGH COUNT PATIENTS